A director at Eurofins Scientific S.E bought 10,000 shares at 45.920EUR and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
EUROFINS SCIENTIFIC - BUY vs. NEUTRAL | EUR125(+33%) Back to Buy recommendation after recent share price consolidation (contact) Good surprises to be expected in the short term… …and the medium term Strong financials allowing the group to remain on the look-out for all opportunities Buy vs Neutral after recent share price consolidation. TP of EUR125 confirmed
EUROFINS SCIENTIFIC - NEUTRAL | EUR125 VS. EUR96 (+5%) All lights at green, but stock correctly valued Review of H1 results and upward revision to 2021 guidance Consensus that already price covid effect in contrast to the group's guidance Strong financials after these results and refinancing TP revised upwards but our opinion confirmed
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
EUROFINS SCIENTIFIC - Conviction BUY Top Picks | EUR96 (+11%) Again outpace expectations Q1 revenue still driven by COVID-19 related activities but not only Group remains particularly active to fight the pandemic Guidance unchanged but results that will be far beyond
Business Services Top Picks Q2 2021: Eurofins on results that will continue to surprise Looking back at Q1 2021: performances in line with our hierarchy of recommendations Q2 outlook: Q1 revenue should again confirm the resilience of the TIC sector Our Top Pick for Q2: Again Eurofins with a TP revised upwards to EUR96 (contact) Next catalysts
EUROFINS SCIENTIFIC - Conviction BUY Top Picks | EUR85(+14%) Positive effect of Covid-19 reagents and resilience of the core business Strong results above expectation despite recent upgrade New guidance excluding Covid-19 that do not seem realistic to us… …an conservative
EUROFINS SCIENTIFIC - Conviction BUY Top Picks | EUR85 (+9%) An adjustment that reinforces our conviction Slight upward revision of our estimates Expectations that we definitely consider too conservative Conviction buy/Top pick confirmed
Business Services Top Picks Q1 2021: Eurofins on conservative guidance Looking back at Q4 2020: Finally Bureau Veritas outperformed Besides the publication of better-than-expected Q3 revenues for Bureau Veritas and Eurofins, the quarter was marked by the decision to implement lockdown measures in many parts of Europe and the Americas, the launch of the first vaccines, but also the rapid spread of a new variant of coronavirus. Q1 outlook: FY results should confirm the resilience of the TIC secto...
The COVID-19 pandemic is having a negative impact on Aroundtown´s (AT1) i) hotel rent collection rates, ii) property valuation gains and iii) portfolio expansion, the group having paused its acquisitions. Therefore, we have reduced our estimates on AT1 and our target price to € 7.90 from € 8.40. However, we confirm our Buy recommendation on AT1 as the beginning of the rollout of the COVID-19 vaccine is likely to result in the start of a recovery of the hotel business from H2 2021e onw...
>Update to 2020 guidance. Welcome but unsurprising - Eurofins yesterday announced an update to its 2020 guidance and held a conference call. This update was expected, as the 2020 guidance was no longer credible in that it had not been reviewed despite the business related to COVID (we expect COVID-related business of € 625m for the year, including € 320m in Q4). The 2021 guidance has not been adjusted despite the fact that management is confident the COVID business wi...
The COVID-19 pandemic is having a negative impact on Aroundtown´s (AT1) i) hotel rent collection rates, ii) property valuation gains and iii) portfolio expansion, the group having paused its acquisitions. Therefore, we have reduced our estimates on AT1 and our target price to € 7.90 from € 8.40. However, we confirm our Buy recommendation on AT1 as the beginning of the rollout of the COVID-19 vaccine is likely to result in the start of a recovery of the hotel business from H2 2021e onw...
>Update de la guidance 2020, bienvenu mais sans surprise - Eurofins a annoncé hier un update de sa guidance 2020 et a tenu une conférence téléphonique. Cet update était attendu, car la guidance 2020 n’était, rappelons-le, plus crédible dans la mesure où elle n’avait pas été updatée malgré le business lié au COVID (nous visons un business COVID de 625 M€ sur l’année, dont 320 M€ sur le seul T4). La guidance 2021 n’est pas ajustée alors que le management est confiant su...
EUROFINS SCIENTIFIC - BUY | EUR77 vs. EUR710 (+10%) Contact: on track to outpace management's objectives Trading update: second lockdown taking a lesser toll… …and IVD should largely drive Q4 growth as seen in Q3 Uncertainties but in all cases results should exceed management expectations Resources for potentially actively taking over the M&A strategy A win/win position whatever the scenario
EUROFINS SCIENTIFIC (FR), a company active in the Health Care Providers industry, sees its general evaluation downgraded to Neutral on account of a double requalification. The independent financial analyst theScreener just removed a fundamental star(s) for a 2 over 4-star rating. As such, market behaviour has also deteriorated and is evaluated as moderately risky. theScreener believes that the loss of a star(s) and the increased risk justifies the general evaluation downgrade, which passes to Ne...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.